Novartis

Advertisement
Kaitlyn D’OnofrioCardiology | October 22, 2018
The U.S. Food and Drug Administration (FDA) has rejected canakinumab to be used to reduce the risk of cardiovascular ...
Read More
Advertisement
Advertisement